Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial - Université de Lyon Access content directly
Journal Articles The Lancet Year : 2018

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Zongo
  • Function : Author
Isabelle Borghini-Fuhrer
  • Function : Author
Aliou Traore
  • Function : Author
Nouhoum Diallo
  • Function : Author
Hamadoun Diakite
  • Function : Author
Sekou Koumare
  • Function : Author
Mohamed Keita
  • Function : Author
Daouda Camara
  • Function : Author
Anyirékun Somé
  • Function : Author
Aboubacar Coulibaly
  • Function : Author
Bouran Sidibe
  • Function : Author
Francois Dao
  • Function : Author
Moctar Coulibaly
  • Function : Author
Hamidou Niangaly
  • Function : Author
  • PersonId : 977152
Boubou Sangare
  • Function : Author
Modibo Diarra
  • Function : Author
Samba Coumare
  • Function : Author
Moïse Kabore
  • Function : Author
San Maurice Ouattara
  • Function : Author
Aissata Barry
  • Function : Author
Désiré Kargougou
  • Function : Author
Noelie Henry
  • Function : Author
Harouna Soré
  • Function : Author
Ismaila Thera
  • Function : Author
Yves Compaore
  • Function : Author
Malick Minkael Sylla
  • Function : Author
Frederic Nikiema
  • Function : Author
Mamadou Saliou Diallo
  • Function : Author
Stephan Duparc
  • Function : Author
Jangsik Shin
  • Function : Author

Domains

Parasitology

Dates and versions

hal-02136477 , version 1 (22-05-2019)

Identifiers

Cite

Issaka Sagara, Abdoul Habib Beavogui, Issaka Zongo, Issiaka Soulama, Isabelle Borghini-Fuhrer, et al.. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet, 2018, 391 (10128), pp.1378-1390. ⟨10.1016/S0140-6736(18)30291-5⟩. ⟨hal-02136477⟩
59 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More